BioMarin (BMRN) Stock Surges on $4.8B Amicus Deal: Latest News, Analyst Forecasts, and What to Watch Next (Dec. 20, 2025)
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ended Friday’s session sharply higher after announcing a blockbuster rare-disease acquisition that immediately reframed the company’s growth story. Shares closed at $61.15, up about 17.7% on the day, with trading volume far above typical levels—classic